| Literature DB >> 35831335 |
Reham S Ibrahim1, Nesrine S El-Mezayen2, Alaa A El-Banna1.
Abstract
Liver cirrhosis is a late-stage liver disease characterized by excessive fibrous deposition triggering portal-hypertension (PH); the prime restrainer for cirrhosis-related complications. Remedies that can dually oppose hepatic fibrosis and lower PH, may prevent progression into decompensated-cirrhosis. Different Astragalus-species members have shown antifibrotic and diuretic actions with possible subsequent PH reduction. However, A.spinosus and A.trigonus were poorly tested for eliciting these actions. Herein, A.spinosus and A.trigonus roots and aerial parts extracts were subjected to comprehensive metabolic-fingerprinting using UHPLC-MS/MS resulting in 56 identified phytoconstituents, followed by chemometric untargeted analysis that revealed variable metabolic profiles exemplified by different species and organ types. Consequently, tested extracts were in-vivo evaluated for potential antifibrotic/anticirrhotic activity by assessing specific markers. The mechanistic prospective to induce diuresis was investigated by analyzing plasma aldosterone and renal-transporters gene-expression. Serum apelin and dimethylarginine-dimethylaminohydrolase-1 were measured to indicate the overall effect on PH. All extracts amended cirrhosis and PH to varying extents and induced diuresis via different mechanisms. Further, An OPLS model was built to generate a comprehensive metabolic-profiling of A.spinosus and A.trigonus secondary-metabolites providing a chemical-based evidence for their efficacious consistency. In conclusion, A.spinosus and A.trigonus organs comprised myriad pharmacologically-active constituents that act synergistically to ameliorate cirrhosis and associated PH.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35831335 PMCID: PMC9279505 DOI: 10.1038/s41598-022-15958-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1UPLC-ESI- TQD-MS base peak chromatograms of Astragalus methanolic extracts in negative ionization mode. A. spinosus aerial parts (A), A. spinosus roots (B), A. trigonus aerial parts (C) and A. trigonus roots (D) chromatograms.
Metabolites identified in Astragalus samples extracts using UPLC-MS in negative ionization mode.
| No | Rt (min.) | [M-H]− | Element composition | MSn ions m/z (-) | Identified compounds | Chemical class |
|---|---|---|---|---|---|---|
| 1 | 1.10 | 341.29 | C15H18O9 | 179.15, 135.14 | Caffeic acid-O-hexoside | Phenolic acid |
| 2 | 1.21 | 191.16 | C7H12O6 | 127.12 | Quinic acid | Phenolic acid |
| 3 | 1.26 | 133.08 | C4H6O5 | 115, 71 | Malic acid | Dicarboxylic acid |
| 4 | 1.35 | 169.11 | C7H6O5 | 125.1 | Gallic acid | Phenolic acid |
| 5 | 1.50 | 353.3 | C16H18O9 | 191.16, 179.15 | Chlorogenic acid | Phenolic acid |
| 6 | 1.60 | 179.15 | C9H8O4 | 135.14 | tr-caffeic acid | Phenolic acid |
| 7 | 1.69 | 197.17 | C9H10O5 | 153.16, 182.14 | Syringic acid | Phenolic acid |
| 8 | 1.83 | 359.31 | C18H16O8 | 197.1, 179.1, 161.13 | Rosmarinic acid | Phenolic acid |
| 9 | 1.88 | 725.63 | C32H38O19 | 593.52, 447.38, 285.23, 133.12, 151.1 | Kaempferol-O-rutinoside-O-arabinoside | Flavonoidal glycoside |
| 10 | 2.32 | 755.65 | C33H40O20 | 623.54, 477.4, 315.26, 271.2, 151.1 | Isorhamnetin-O-rutinoside-O-arabinoside | Flavonoidal glycoside |
| 11 | 2.67 | 341.29 | C12H22O11 | 113.09, 119.1, 161.13, 179.15 | Dihexose | Disaccharide |
| 12 | 2.87 | 609.51 | C27H30O16 | 301.23, 272.21, 255.2, 151.1 | Rutin (quercetin-3-O-rutinoside) | Flavonoidal glycoside |
| 13 | 10.71 | 595.53 | C27H32O15 | 449.39, 287.24, 151.1 | Eriodyctiol-7-O-rutinoside | Flavonoidal glycoside |
| 14 | 10.79 | 623.54 | C28H32O16 | 315.26, 300.22, 271.2, 151.1 | Isorhamnetin-3-O-rutinoside | Flavonoidal glycoside |
| 15 | 11.31 | 193.18 | C10H10O4 | 178.15,149.17 | ferulic acid | Phenolic acid |
| 16 | 11.93 | 531.44 | C25H24O13 | 283, 136.11, 211.19, 239.2, 268.22 | Calycosin-7-O-B-D-glucoside-6``-O-malonate | Flavonoidal glycoside |
| 17 | 12.39 | 515.44 | C25H24O12 | 429.4, 267.26 | Formononetin-7-O-glucoside-6``-O-malonate | Flavonoidal glycoside |
| 18 | 13.33 | 579.53 | C27H32O14 | 271.25, 151.1, 119.14, 107.09 | Naringin | Flavonoidal glycoside |
| 19 | 13.81 | 463.37 | C21H20O12 | 301.23, 272.21, 255.2, 151.1 | Hyperoside (Quercetin-3-O-galactoside) | Flavonoidal glycoside |
| 20 | 13.98 | 447.37 | C21H20O11 | 357.29, 327.27, 285.23 | Orientin (Luteolin-8-C-glucoside) | Flavonoidal glycoside |
| 21 | 14.04 | 447.37 | C21H20O11 | 285.23, 133.12, 151.1 | Astragalin (Kaempferol-3-O-glucoside) | Flavonoidal glycoside |
| 22 | 14.15 | 449.39 | C21H22O11 | 287.24, 151.1 | Eriodyctiol-7-O-glucoside | Flavonoidal glycoside |
| 23 | 14.20 | 477.4 | C22H22O12 | 315.26, 300.22, 271.2, 151.1 | Isorhamnetin-3-O-B-D-glucoside | Flavonoidal glycoside |
| 24 | 14.33 | 447.37 | C21H20O11 | 301.23, 272.21, 255.2, 151.1 | Quercetin-3-O-rhamnoside (Quercitrin) | Flavonoidal glycoside |
| 25 | 15.91 | 431.37 | C21H20O10 | 341.29, 311.27, 269.23 | Vitexin (Apigenin-8-C-glucoside) | Flavonoidal glycoside |
| 26 | 18.44 | 461.4 | C22H22O11 | 299.26 | Rhamnocitrin-O-glucoside | Flavonoidal glycoside |
| 27 | 20.16 | 461.4 | C22H22O11 | 299.26 | Pratensein-7-O-B-D-glucoside | Flavonoidal glycoside |
| 28 | 21.21 | 429.4 | C22H22O9 | 267.26 | Ononin (Formononetin-7-O-glucoside) | Flavonoidal glycoside |
| 29 | 21.36 | 461.44 | C23H26O10 | 299.3 | 9,10-dimethoxypterocarpan-3-O-B-D-glucoside | Flavonoidal glycoside |
| 30 | 21.53 | 461 | 299.1, 268.8 | (-)-methylinissolin-3-O-B-D-glucoside | Flavonoidal glycoside | |
| 31 | 21.89 | 317.23 | C15H10O8 | 179.11, 151.1, 137.11 | Myricetin | Flavonoidal aglycone |
| 32 | 22.01 | 301.23 | C15H10O7 | 272.21, 255.2, 151.1 | Quercetin | Flavonoidal aglycone |
| 33 | 22.11 | 481.43 | C25H22O10 | 301.2, 453.42 | Silymarin | Flavonolignans |
| 34 | 22.30 | 271.25 | C15H12O5 | 151.1, 119.14, 107.09 | Naringenin | Flavonoidal aglycone |
| 35 | 22.69 | 301.27 | C16H14O6 | 286.24, 164.12, 136.15 | Hesperetin | Flavonoidal aglycone |
| 36 | 22.91 | 253.23 | C15H10O4 | 209.22, 135.1 | Daidzein | Flavonoidal aglycone |
| 37 | 23.19 | 255.25 | C15H12O4 | 135.1, 119.14 | Isoliquiritigenin | Chalcone derivative |
| 38 | 23.45 | 285.23 | C15H10O6 | 133.12, 151.1 | Kaempferol | Flavonoidal aglycone |
| 39 | 23.69 | 269.23 | C15H10O5 | 225.22, 151.1, 117.13 | Apigenin | Flavonoidal aglycone |
| 40 | 24.10 | 315.26 | C16H12O7 | 300.22, 271.2, 151.1 | Isorhamnetin | Flavonoidal aglycone |
| 41 | 24.56 | 253.23 | C15H10O4 | 209.22, 151.1 | Chrysin | Flavonoidal aglycone |
| 42 | 28.25 | 283.26 | C16H12O5 | 136.11, 211.19, 239.2, 268.22 | Calycosin | Flavonoidal aglycone |
| 43 | 28.39 | 783.96 | C41H68O14 | 651.85, 621.82, 489.71, 179.15, 161.13, 149.12, 131.11 | Astragaloside IV | Cycloartane saponin |
| 44 | 29.05 | 826 | C43H70O15 | 764.94, 632.83, 88.7 | Astragaloside II | Cycloartane saponin |
| 45 | 29.43 | 942.12 | C48H78O18 | 795.98, 633.84, 439.7, 421.68 | Soyasaponin I | Oleanane saponin |
| 46 | 30.04 | 868.04 | C45H72O16 | 824.99, 781.95, 692.88, 662.85, 488.7 | Astragaloside I | Cycloartane saponin |
| 47 | 32.43 | 912.09 | C47H76O17 | 868.08, 647.87 | Astragaloside VIII | Cycloartane saponin |
| 48 | 33.88 | 277.42 | C18H30O2 | 259.4 | Linolenic acid | polyunsaturated omega-3 fatty acid |
| 49 | 34.03 | 329.45 | C18H34O5 | 171.21 | 9,10,13-trihydroxy-11-octadecenoic acid | monounsaturated fatty acid |
| 50 | 34.18 | 269.44 | C17H34O2 | 238.41, 74.08 | Palmitic acid methyl ester | saturated fatty acid ester |
| 51 | 34.53 | 269.44 | C17H34O2 | 238.41, 74.08, 43.09 | 14-methyl pentadecanoic acid methyl ester | saturated fatty acid ester |
| 52 | 34.75 | 279.44 | C18H32O2 | 261.42 | Linoleic acid | polyunsaturated omega-6 fatty acid |
| 53 | 34.93 | 293.47 | C19H34O2 | 279.44, 261.42 | Linoleic acid methyl ester | polyunsaturated omega-6 fatty acid ester |
| 54 | 35.00 | 295.48 | C19H36O2 | 264.45, 221.4, 74.08, 55.1 | 16-octadecenoic acid methyl ester | monounsaturated fatty acid ester |
| 55 | 35.79 | 369.56 | C22H42O4 | 55.1 | Hexanedioic acid dioctyl ester | saturated fatty acid diester |
| 56 | 36.11 | 339.58 | C22H44O2 | 321.56, 295.57 | Behenic acid | saturated fatty acid |
Figure 2Score scatter plot of principal component analysis using UPLC-ESI- TQD-MS, n = 3. represented by first two components.
Figure 3HCA- heat map showing the most discriminatory metabolites in each cluster.
Figure 4The effect of different Astragalus extracts on liver cirrhosis markers and their coefficient plot of OPLS model. (A): Comparison between different groups according to hepatic concentration of different cirrhosis parameters, (B): Coefficient plot of OPLS model for liver cirrhosis parameters; (1) TGF-ꞵ (2) MMP-2 (3) RXR. ANOVA test was used to compare between the different groups with Post Hoc Test (Tukey) to compare different groups. *: Statistically significant at p ≤ 0.05, **: Statistically significant at p ≤ 0.001, N: Statistically non-significant (p > 0.05), n = 8; all results are presented as mean ± SD. (Cirr.: induced cirrhosis by i.p. administration of CCl4 (diluted 1:6 with mineral oil) as follows: The first 10 doses were received every 5 days, the subsequent 10 doses were administered every 4 days, and the last 7 doses were given every 3 days, As: Astragalus spinosus, At: Astragalus trigonus, ar: aerial organs, rt: root organs, D1: low dose, D2: medium dose, D3: high dose, MMP2: matrix metalloproteinase 2, TGF-ꞵ: transforming growth factor beta, RXR: retinoid-X receptor, ALT: Alanine aminotransferase and AST: aspartate aminotransferase.
Figure 5The effect of different Astragalus extracts on serum markers of hepatocytes integrity and liver synthetic function and their coefficient plot of OPLS model. (A): Comparison between different groups according to serum markers of hepatocytes integrity and liver synthetic function, (B): Coefficient plot of OPLS model for serum markers of hepatocytes integrity and liver synthetic function; (1) ALT (2) AST (3) albumin. ANOVA test was used to compare between the different groups with Post Hoc Test (Tukey) to compare different groups. *: Statistically significant at p ≤ 0.05, **: Statistically significant at p ≤ 0.001, N: Statistically non-significant (p > 0.05), n = 8; all results are presented as mean ± SD. (Cirr.: induced cirrhosis by i.p. administration of CCl4 (diluted 1:6 with mineral oil) as follows: The first 10 doses were received every 5 days, the subsequent 10 doses were administered every 4 days, and the last 7 doses were given every 3 days, As: Astragalus spinosus, At: Astragalus trigonus, ar: aerial organs, rt: root organs, D1: low dose, D2: medium dose, D3: high dose, ALT: Alanine aminotransferase and AST: aspartate aminotransferase.
Figure 6The effect of different Astragalus extracts on mRNA expression of proximal convoluted tubule and the thick ascending limb of the loop of Henle transporters and their coefficient plot of OPLS model. (A): Comparison between different groups according to mRNA expression of different renal transporters acting on proximal convoluted tubule and loope of Henle, (B): Coefficient plot of OPLS model for diuretic mechanisms; (1) NHE-1 (2) Aquaporin (3) NKCC2. ANOVA test was used to compare between the different groups with Post Hoc Test (Tukey) to compare different groups. *: Statistically significant at p ≤ 0.05, **: Statistically significant at p ≤ 0.001, N: Statistically non-significant (p > 0.05), n = 8; all results are presented as mean ± SD. (Cirr.: induced cirrhosis by i.p. administration of CCl4 (diluted 1:6 with mineral oil) as follows: The first 10 doses were received every 5 days, the subsequent 10 doses were administered every 4 days, and the last 7 doses were given every 3 days, As: Astragalus spinosus, At: Astragalus trigonus, ar: aerial organs, rt: root organs, D1: low dose, D2: medium dose, D3: high dose, NHE1: sodium–hydrogen antiporter 1, NKCC 2: Na–K–Cl co-transporter 2.
Figure 7The effect of different Astragalus extracts on mRNA expression of the distal convoluted tubule transporters and collecting ducts mechanisms and their coefficient plot of OPLS model. (A): Effect of different Astragalus extracts on the expression of different renal transporters of the distal convoluted tubule and collecting ducts mechanisms, (B): Coefficient plot of OPLS model for diuretic mechanisms; (1) NCC (2) ENaC (3) aldosterone. ANOVA test was used to compare between the different groups with Post Hoc Test (Tukey) to compare different groups. *: Statistically significant at p ≤ 0.05, **: Statistically significant at p ≤ 0.001, N: Statistically non-significant (p > 0.05), n = 8; all results are presented as mean ± SD. (Cirr.: induced cirrhosis by i.p. administration of CCl4 (diluted 1:6 with mineral oil) as follows: The first 10 doses were received every 5 days, the subsequent 10 doses were administered every 4 days, and the last 7 doses were given every 3 days, As: Astragalus spinosus, At: Astragalus trigonus, ar: aerial organs, rt: root organs, D1: low dose, D2: medium dose, D3: high dose, NCC: sodium-chloride symporter and ENaC: epithelial sodium channel.
Figure 8The effect of different Astragalus extracts on portal hypertension markers and their coefficient plot of OPLS model. (A): Effect of different Astragalus extracts on PH markers, (B): Coefficient plot of OPLS model for PH markers; (1) apelin (2) DDAH-1. ANOVA test was used to compare between the different groups with Post Hoc Test (Tukey) to compare different groups. *: Statistically significant at p ≤ 0.05, **: Statistically significant at p ≤ 0.001, N: Statistically non-significant (p > 0.05), n = 8; all results are presented as mean ± SD. (Cirr.: induced cirrhosis by i.p. administration of CCl4 (diluted 1:6 with mineral oil) as follows: The first 10 doses were received every 5 days, the subsequent 10 doses were administered every 4 days, and the last 7 doses were given every 3 days, As: Astragalus spinosus, At: Astragalus trigonus, ar: aerial organs, rt: root organs, D1: low dose, D2: medium dose, D3: high dose, DDAH1: dimethylarginine dimethylaminohydrolase 1.
% decrease in mRNA expression of renal transporters and plasma aldosterone upon treatment with the highest tested dose of each extract compared to positive control group.
| NHE1 (%) | Aquaporin-1 (%) | NKCC2 (%) | NCC (%) | ENaC (%) | Aldosterone (%) | |
|---|---|---|---|---|---|---|
| As-rt D3 | 21.62 | 29.44 | 13.57 | 0.74 | 6.49 | 32.38 |
| As-ar D3 | 10.27 | 7.22 | 9.29 | 14.81 | 1.95 | 42.30 |
| At-ar D3 | 17.30 | 26.11 | 16.43 | 11.85 | 3.25 | 31.33 |
| At-rt D3 | 1.08 | 2.22 | 1.43 | 2.96 | 18.83 | 43.08 |
As: Astragalus spinosus, At: Astragalus trigonus, ar: aerial organs, rt: root organs, D3: high dose, NKCC 2: Na–K-Cl co-transporter 2, NCC: sodium-chloride symporter, NHE1: sodium–hydrogen antiporter 1 and ENaC: epithelial sodium channel.
Used oligonucleotide primers in the present study for RT-PCR analysis.
| Primer | Sequence | Product length | Accession number | |
|---|---|---|---|---|
| aquaporin 1 (Aqp1) | Forward | 5’-TTGCAAGGACCTGATGCTGT-3’ | 139 | NM_012778.1 |
| Reverse | 5’-TAACGGCACAGTGGTAGAGC-3’ | |||
| NKCC2 (Slc12a1) | Forward | 5’-AAGCGGGAATTGGTCTTGGA-3’ | 81 | NM_001270617.1 |
| Reverse | 5’-TTGCAGAAGTTGACAACCCAGT-3’ | |||
| NCC (Slc12a3) | Forward | 5'- TCCCAGTATTGGGTGTGCAA-3' | 115 | NM_019345.3 |
| Reverse | 5'- CACATGGGTCCTCAGGATGG-3' | |||
| NHE1 (Slc9a1) | Forward | 5'-ACCCCTCGTCTAGACCACTC-3' | 132 | NM_012652.1 |
| Reverse | 5'-CTCAGGGGTTGGACAGACAC-3' | |||
| β-actin | Forward | 5'- ATCATTGCTCCTCCTGAGCG-3' | 179 | NM_031144.3 |
| Reverse | 5'- GAAAGGGTGTAAAACGCAGCTC-3' | |||